Lanuti M. Commentary: Induction antiangiogenesis for stage IIIA-N2 non-small cell lung cancer is not the answer yet: Optimal induction for operable disease is a clear work in progress. J Thorac Cardiovasc Surg 2022 Jan 8. pii: S0022-5223(22)00007.
PMID: 35125212